I consider urology to be a very unique field, one that I am lucky to be part of. Recently, though, I have begun to wonder whether the medical community (not necessarily the urology community) has been too quick to embrace the widespread use of testosterone replacement therapy.
A new study suggests that the role estrogen plays in influencing male libido may be more significant than previously thought. The findings carry implications for a variety of clinical situations, ranging from the use of testosterone replacement to boost flagging libido and androgen therapies in men with prostate cancer.
Intralesional injection of collagenase clostridium histolyticum (CCH [XIAFLEX]) improves the physical and psychological aspects of Peyronie’s disease in men regardless of erectile dysfunction severity and whether they have a history of prior treatment or prostatectomy, according to a recent study.
The safety of testosterone replacement therapy has been the subject of two recently published studies, which were followed by a January 2014 FDA announcement that the agency is investigating the risk of stroke, heart attack, and death in men taking TRT. Additional data on the safety of TRT, including its use in men following radical prostatectomy, will be presented at the AUA meeting, said John J. Mulcahy, MD, PhD.
This guide features products and services from manufacturers that are exhibiting at the AUA annual meeting in Orlando. Exhibit hall booth numbers have been included so that you can search for product demonstrations and exhibits that are of particular interest to you.